| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
beta-catenin-IN-6 targets beta-catenin, a key transcriptional co-activator and central node in the canonical Wnt signaling pathway. By inhibiting beta-catenin, it disrupts the formation of the beta-catenin/TCF/LEF transcription factor complex, thereby suppressing the expression of Wnt target genes involved in cell proliferation and survival.
|
|---|---|
| ln Vitro |
β-catenin-IN-6 (compound 9) exhibits inhibitory effects on both LoVo and HT29 cells, with IC50 values of 1.37 μM and 1.4 μM, respectively, after 24 hours. Human colorectal cancer cell lines exhibit cytostatic effects when exposed to β-catenin-IN-6 [1].
beta-catenin-IN-6 (compound 9) inhibits the viability of human colorectal cancer cell lines LoVo and HT29 with IC50s of 1.4 microM and 1.37 microM, respectively, after 24 hours of treatment. It also shows cell growth inhibition against several other human colorectal cancer lines, confirming its anti-proliferative activity in vitro. |
| ln Vivo |
β-catenin-IN-6 (compound 9) has a low bioavailability[1]. Without altering body weight, β-catenin-IN-6 (18.75 mg/kg; intraperitoneal injection; once daily for 7 days) can decrease tumor volume in mice[1]. In the β-catenin/RK3E mouse model, compound 13 (150 mg/kg; intraperitoneal injection, once weekly) prevents the formation of xenograft tumors[2].
In a beta-catenin/RK3E mouse model, beta-catenin-IN-6 (compound 9) demonstrates inhibitory effects, although it is noted to display poor bioavailability, which may limit its in vivo efficacy. The compound suppresses tumor growth in this mouse model, supporting its potential for studying Wnt/beta-catenin-driven cancers. |
| Enzyme Assay |
A standard biochemical beta-catenin/TCF transcription assay can be performed using a SuperTopFlash (STF) luciferase reporter system. HEK293 STF cells or similar reporter cell lines are treated with increasing concentrations of beta-catenin-IN-6 for 16-24 hours in the presence of Wnt3a stimulation. Luciferase activity is then measured, and the IC50 for inhibition of beta-catenin-mediated transcription is calculated.
|
| Cell Assay |
Cytotoxicity is typically assessed using the MTT or CellTiter-Glo assay. LoVo and HT29 human colorectal cancer cells are seeded in 96-well plates and treated with a concentration range of beta-catenin-IN-6 (0.1-10 microM) for 72 hours. After incubation, MTT reagent or CellTiter-Glo solution is added, and absorbance or luminescence is measured to determine the IC50 values of 1.37-1.40 microM.
|
| Animal Protocol |
Animal/Disease Models: Nude mice bearing subcutaneous (sc) β-catenin/ RK3E tumors[1][2]
Doses: 18.75 mg/kg, 37.5 mg/kg, 75.1 mg/kg, 150 mg/kg Route of Administration: IP; one time/day for 7 days Experimental Results: Inhibited tumor growth up to 66% in mouse model. demonstrated dose-dependent inhibition on tumor growth and volume. The in vivo efficacy of beta-catenin-IN-6 is evaluated in a beta-catenin/RK3E mouse model. Female BALB/c nude mice are injected subcutaneously with beta-catenin/RK3E cells. Once tumors reach 100-150 mm3, mice are randomized and treated with beta-catenin-IN-6 via oral gavage at various doses (e.g., 10-50 mg/kg). Tumor volumes are measured with calipers every 2-3 days over a treatment period of 2-4 weeks to assess tumor growth inhibition (TGI). |
| ADME/Pharmacokinetics |
beta-catenin-IN-6 is reported to display poor bioavailability, which limits its suitability for in vivo pharmacology studies. Detailed pharmacokinetic parameters such as half-life, Cmax, and AUC have not been reported in detail.
|
| Toxicity/Toxicokinetics |
No specific toxicology data is reported for beta-catenin-IN-6. The compound is currently a research tool; detailed preclinical safety profiling has not been extensively characterized.
|
| References |
|
| Additional Infomation |
beta-catenin-IN-6 is a beta-catenin inhibitor targeting the canonical Wnt/beta-catenin signaling pathway. It inhibits human colorectal cancer cell proliferation and shows efficacy in a beta-catenin/RK3E mouse model. The compound has CAS number 1039731-99-1, molecular formula C22H19ClN6O, and molecular weight 418.88. Its poor bioavailability is noted as a limitation for in vivo applications.
|
| Molecular Formula |
C22H19CLN6O
|
|---|---|
| Molecular Weight |
418.88
|
| Exact Mass |
418.131
|
| CAS # |
1039731-99-1
|
| PubChem CID |
25025509
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.501
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
558
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CNC1=NC2=CC=CC=C2C(=N1)NCC3=CC=C(C=C3)NC(=O)C4=CN=C(C=C4)Cl
|
| InChi Key |
PIROHBFQHMKAPE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H19ClN6O/c1-24-22-28-18-5-3-2-4-17(18)20(29-22)26-12-14-6-9-16(10-7-14)27-21(30)15-8-11-19(23)25-13-15/h2-11,13H,12H2,1H3,(H,27,30)(H2,24,26,28,29)
|
| Chemical Name |
6-chloro-N-[4-[[[2-(methylamino)quinazolin-4-yl]amino]methyl]phenyl]pyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (238.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3873 mL | 11.9366 mL | 23.8732 mL | |
| 5 mM | 0.4775 mL | 2.3873 mL | 4.7746 mL | |
| 10 mM | 0.2387 mL | 1.1937 mL | 2.3873 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
